Sagimet Biosciences - SeriNASDAQ: SGMT

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

17 July 2023

Next earnings report:

13 November 2024

Last dividends:

N/A

Next dividends:

N/A
$182.23 M
-55%vs. 3y high
51%vs. sector
-vs. 3y high
-vs. sector
-78%vs. 3y high
40%vs. sector
-vs. 3y high
-vs. sector

Price

pre-market | 46 min ago
$5.66-$0.09(-1.57%)

Dividend

No data over the past 3 years

Analysts recommendations

Institutional Ownership

SGMT Latest News

Sagimet Soars: FDA Breakthrough Therapy Designation And Lancet Review Validate Denifanstat
seekingalpha.com18 October 2024 Sentiment: POSITIVE

Sagimet Biosciences' Denifanstat shows significant potential in treating MASH, with FDA Breakthrough Therapy designation and peer-reviewed validation, supporting a "Strong Buy" rating. Denifanstat's unique FASN inhibition mechanism effectively reduces liver fibrosis, positioning it as a superior treatment for advanced MASH compared to competitors like Tirzepatide. SGMT's robust financials, including $188.5 million in liquidity and no debt, provide a solid foundation for advancing Denifanstat through Phase 3 trials.

Sagimet Announces Oral Presentation at the 8th Annual MASH Drug Development Summit
globenewswire.com12 September 2024 Sentiment: POSITIVE

SAN MATEO, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced that an oral presentation highlighting denifanstat's anti-fibrotic activity in metabolic dysfunction-associated steatohepatitis (MASH) will be given at the 8th Annual MASH Drug Development Summit being held in Boston on September 24-26, 2024.

Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors
globenewswire.com01 August 2024 Sentiment: POSITIVE

SAN MATEO, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced the appointments of two biotechnology industry leaders, Anne Phillips and Jennifer Jarrett, to the board of directors of the Company, effective August 1, 2024.

Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 23, 2024
globenewswire.com16 May 2024 Sentiment: POSITIVE

Dr. Scott Friedman will discuss the unmet need in MASH and present Sagimet's topline data from the FASCINATE-2 Phase 2b clinical trial of denifanstat in MASH.

Sagimet Biosciences To Present at the H.C. Wainwright 7th Annual NASH Investor Conference
GlobeNewsWire18 October 2023 Sentiment: POSITIVE

SAN MATEO, Calif., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic pathways, today announced that management will participate in a fireside chat and one-on-one investor meetings at the H.C. Wainwright 7th Annual NASH Investor Conference on Tuesday, October 24, 2023, at 3:00 p.m. ET / 12:00 p.m. PT.

Sagimet Biosciences: Recent IPO With Emerging Positive Data In NASH
Seeking Alpha27 September 2023 Sentiment: POSITIVE

Sagimet Biosciences Inc. develops FASN inhibitors for diseases related to dysfunctional lipid metabolism. Their lead candidate, Denifanstat, shows promising results in treating nonalcoholic steatohepatitis and acne. The company has a strong safety profile and sufficient cash to last until 2025.

What type of business is Sagimet Biosciences - Seri?

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.

What sector is Sagimet Biosciences - Seri in?

Sagimet Biosciences - Seri is in the Healthcare sector

What industry is Sagimet Biosciences - Seri in?

Sagimet Biosciences - Seri is in the Biotechnology industry

What country is Sagimet Biosciences - Seri from?

Sagimet Biosciences - Seri is headquartered in United States

When did Sagimet Biosciences - Seri go public?

Sagimet Biosciences - Seri initial public offering (IPO) was on 17 July 2023

What is Sagimet Biosciences - Seri website?

https://www.sagimet.com

Is Sagimet Biosciences - Seri in the S&P 500?

No, Sagimet Biosciences - Seri is not included in the S&P 500 index

Is Sagimet Biosciences - Seri in the NASDAQ 100?

No, Sagimet Biosciences - Seri is not included in the NASDAQ 100 index

Is Sagimet Biosciences - Seri in the Dow Jones?

No, Sagimet Biosciences - Seri is not included in the Dow Jones index

When was Sagimet Biosciences - Seri the previous earnings report?

No data

When does Sagimet Biosciences - Seri earnings report?

The next expected earnings date for Sagimet Biosciences - Seri is 13 November 2024